Proline-rich sequence is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
==== Nitrogen ==== The nitrogen stable isotope system is based on the relative enrichment/depletion of 15N in comparison to 14N in δ15N. Carbon and nitrogen stable isotope analyses are complementary in paleodiet studies. Nitrogen isotopes in bone collagen are ultimately derived from dietary protein, while carbon can be contributed by protein, carbohydrate, or fat. δ13C values help distinguish between dietary protein and plant sources while systematic increases in δ15N values as you move up in trophic level helps determine the position of protein sources in the food web. 15N increases 3-4% with each trophic step upward. It has been suggested that the relative difference between human δ15N values and animal protein values scales with the proportion of that animal protein in the diet, though this interpretation has been questioned due to contradictory views on the impact of nitrogen intake through protein consumption and nitrogen loss through waste release on 15N enrichment in the body. Variations in nitrogen values within the same trophic level are also considered. Nitrogen variations in plants, for example, can be caused by plant-specific reliance on nitrogen gas which causes the plant to mirror atmospheric values. Enriched or higher δ15N values can be achieved in plants that grew in soil fertilized by animal waste. Nitrogen isotopes have been used to estimate the relative contributions of legumes verses nonlegumes, as well as terrestrial versus marine resources.
=== Pacific islands === During an El Niño event, New Zealand tends to experience stronger or more frequent westerly winds during their summer, which leads to an elevated risk of drier than normal conditions along the east coast. There is more rain than usual though on New Zealand's West Coast, because of the barrier effect of the North Island mountain ranges and the Southern Alps. Fiji generally experiences drier than normal conditions during an El Niño, which can lead to drought becoming established over the Islands. However, the main impacts on the island nation is felt about a year after the event becomes established. Within the Samoan Islands, below average rainfall and higher than normal temperatures are recorded during El Niño events, which can lead to droughts and forest fires on the islands. Other impacts include a decrease in the sea level, possibility of coral bleaching in the marine environment and an increased risk of a tropical cyclone affecting Samoa. In the late winter and spring during El Niño events, drier than average conditions can be expected in Hawaii. On Guam during El Niño years, dry season precipitation averages below normal, but the probability of a tropical cyclone is more than triple what is normal, so extreme short duration rainfall events are possible. On American Samoa during El Niño events, precipitation averages about 10 percent above normal, while La Niña events are associated with precipitation averaging about 10 percent below normal.
== Further reading == Gunten, Hans R. von (1995). "Radioactivity: A Tool to Explore the Past" (PDF). Radiochimica Acta. 70–71 (s1): 305–413. doi:10.1524/ract.1995.7071.special-issue.305. S2CID 100441969. Magill, Joseph; Galy, Jean (2005). "Archaeology and Dating". Radioactivity Radionuclides Radiation. Springer Berlin Heidelberg. pp. 105–115. Bibcode:2005rrr..book.....M. doi:10.1007/3-540-26881-2_6. ISBN 978-3-540-26881-9. Allègre, Claude J (4 December 2008). Isotope Geology. Cambridge University Press. ISBN 978-0-521-86228-8. McSween, Harry Y; Richardson, Steven Mcafee; Uhle, Maria E; Uhle, Professor Maria (2003). Geochemistry: Pathways and Processes (2 ed.). Columbia University Press. ISBN 978-0-231-12440-9. Harry y. Mcsween, Jr; Huss, Gary R (29 April 2010). Cosmochemistry. Cambridge University Press. ISBN 978-0-521-87862-3. Rollinson, Hugh R. (1993). Using geochemical data: evaluation, presentation, interpretation. Harlow: Longman. ISBN 0-582-06701-4. OCLC 27937350.
== Interaction with juvenile hormone == Juvenile hormone is synthesised in the corpora allata. In every insect tested, at least one of the three types of Allatostatin inhibits the biosynthesis of juvenile hormone. This is achieved by paracrine release of Allatostatin from neurons in the brain which terminate in the corpora allata. The signal is transduced by GPCR receptors, but the intracellular pathway is not yet known. Other amine and neuropeptide neurotransmitters may also inhibit juvenile hormone biosynthesis.
Sources: en.wikipedia.org
3. Competitive inhibition: Some drugs may share the same P-450 specificity and thus competitively block their biotransformation. This may lead to accumulation of drugs metabolized by the enzyme. This type of drug interaction may also reduce the rate of generation of toxic metabolites.
=== Match schedule === The match schedule, without group assignments, was announced on February 4, 2024. On June 13, FIFA released an updated schedule, with specific pairings assigned to venues for the knockout stage. The full schedule was unveiled in a live broadcast on December 6, 2025, the day after the draw. The opening match of the tournament included Mexico, and took place on June 11, 2026, at the Estadio Azteca in Mexico City. Canada's first match occurred on June 12 at BMO Field in Toronto, while the United States' opening match took place on the same day at SoFi Stadium in Inglewood. The national team of each host nation played its three group stage matches in its own country. AT&T Stadium in Arlington hosted the most matches of any venue, with nine. The U.S. hosted 78 matches, including all quarterfinals, semifinals, and the final, which was played at MetLife Stadium in East Rutherford on July 19. Canada and Mexico each hosted 13 matches. Each tournament venue, except for the Estadio Akron, hosted at least one knockout stage match. The match schedule overlapped with the 2026 Canadian Football League season, resulting in scheduling conflicts and loss of home games for the Toronto Argonauts and BC Lions. The match schedule also affected the 2026 Major League Baseball season schedules of the Kansas City Royals, Philadelphia Phillies, Seattle Mariners, and Texas Rangers, with home stadiums near World Cup venues. Host cities were geographically grouped into three regions:
Fluoroalanine, specifically 3-fluoro-alanine, is a fluorinated analogue of the amino acid alanine. Historically considered as an antibiotic, it also has potential applications as a radioactive tracer in positron emission tomography (PET).
=== Implicated in deaths === In June 2009, an FDA advisory panel recommended that Percocet, Vicodin, and every other combination of acetaminophen with narcotic analgesics be limited in their sales because of their contributions to an alleged 400 acetaminophen-related deaths in the U.S. each year, that were attributed to acetaminophen overdose and associated liver damage. In December 2009, a study found a fivefold increase in oxycodone-related deaths in Ontario, Canada (mostly accidental) between 1991 and 2007; this led to a doubling of all opioid-related deaths in Ontario over the same period.
Heterocodeine (6-methoxymorphine) is an opiate derivative, the 6-methyl ether of morphine, and a structural isomer of codeine; it is called "hetero-" because it is the reverse isomer of codeine. Heterocodeine was first synthesised in 1932 and first patented in 1935. It can be made from morphine by selective methylation. Codeine is the natural mono-methyl ether, but must be metabolized for activity (that is, it is a prodrug). In contrast the semi-synthetic mono-methyl ether, heterocodeine is a direct agonist. The 6,7,8,14 tetradehydro 3,6 methyl di-ether of morphine is thebaine. Heterocodeine is 6 times more potent than morphine due to having a substitution at the 6-hydroxy position, in a similar manner to 6-acetylmorphine. The drug methyldihydromorphine (dihydroheterocodeine) is a derivative of heterocodeine. Like the morphine metabolite morphine-6-glucuronide, 6-position branches (esters or ethers) of morphine bind to the otherwise unagonized human mu receptor subtype mu-3 (or μ3); as well as the 6-acetylmorphine metabolite of heroin this includes heterocodeine. The relative strength of heterocodeine to codeine has been published as 50, 72, 81, 88, 93, 96, and 108 ×. It is not mentioned specifically in the Controlled Substances Act 1970 but is a Schedule II controlled substance as an analogue of morphinan or morphine under the morphine structure rules of the Analogues Act; in other countries it is usually controlled as a strong opioid. Homocodeine is a synonym for pholcodine.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.